文献速递消化道肿瘤与早癌

遗传变异与II-III期结肠癌患者生存相关

Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-12-04

该研究对两项随机III期试验(NCCTG N0147和NSABP C-08)中4974例已切除II-III期结肠癌患者进行全基因组关联分析,发现染色体7p15.2位点与总生存期显著相关,其中rs76766811仅在非裔美国人中与总生存期和无病生存期相关。

要点

  • rs76766811在非裔美国人中常见(次要等位基因频率约18%),在欧洲裔美国人中罕见(<0.1%)。
  • 非裔美国人中rs76766811与总生存期相关(HR 2.82,95%CI 1.88-4.23,P=5.0x10-07)。
  • 非裔美国人中rs76766811与无病生存期相关(HR 2.27,95%CI 1.62-3.18,P=1.8x10-06)。

核心结论

  • 在两项II-III期结肠癌试验数据分析中,rs76766811被确定为非裔美国患者中的潜在预后变异。
  • 该发现需要在其他研究人群中确认。

研究设计与样本

  • 对NCCTG N0147(随机III期试验,已切除III期结肠癌)和NSABP C-08(III期试验,比较已切除II或III期结肠癌的治疗方案)进行事后分析。
  • 对4974例患者血样DNA进行基因型分析,采用Cox比例风险回归评估每个SNP与总生存期和无病生存期的关联,调整诊断年龄、性别、治疗组和遗传祖先主成分。
  • 分别分析N0147和C-08研究,结果通过固定效应荟萃分析合并。

主要发现

  • 染色体7p15.2位点与总生存期显著相关(P ≤ 5x10-08)。
  • 该位点最显著变异rs76766811(P = 1.6x10-08)在非裔美国人中常见(次要等位基因频率约18%),在欧洲裔美国人中罕见(次要等位基因频率<0.1%)。
  • 在自我报告祖先分层内,该变异仅在非裔美国人中与总生存期相关(HR 2.82,95%CI 1.88-4.23,P = 5.0x10-07)和无病生存期相关(HR 2.27,95%CI 1.62-3.18,P = 1.8x10-06)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Many genetic variants have been associated with colorectal cancer risk, although few have been associated with survival times of patients. Identification of genetic variants associated with survival times might improve our understanding of disease progression and aid in outcome prediction. We performed a genome-wide association study to identify variants associated with colon cancer survival time. METHODS: We performed a post hoc analysis of data from NCCTG N0147 (Alliance), a randomized phase 3 trial of patients with resected stage III colon cancer, and from NSABP C-08 (NRG), a phase 3 trial that compared therapy regimens for patients with resected stage II or III colon cancer. Genotype analyses were performed on DNA from blood samples from 4974 patients. We used Cox proportional hazards regression to evaluate the association of each single nucleotide polymorphism with times of overall survival and disease-free survival, adjusting for age at diagnosis, sex, treatment group, and principal components of genetic ancestry. We performed the analysis for studies N0147 and C-08 separately, and results were combined in a fixed-effects meta-analysis. RESULTS: A locus on chromosome 7p15.2 was significantly associated with overall survival time (P ≤ 5x10-08). The most significant variant at this locus, rs76766811 (P = 1.6x10-08), is common among African Americans (minor allele frequency, approximately 18%) but rare in European Americans (minor allele frequency <0.1%). Within strata of self-reported ancestry, this variant was associated with times of overall survival and disease-free survival in only African Americans (hazard ratio for overall survival, 2.82; 95% CI, 1.88-4.23; P = 5.0x10-07 and hazard ratio for disease-free survival, 2.27; 95% CI, 1.62-3.18; P = 1.8x10-06). CONCLUSIONS: In an analysis of data from 2 trials of patients with stage II or III colon cancer, we identified rs76766811 as a potential prognostic variant in African American patients. This finding should be confirmed in additional study populations. ClinicalTrials.gov Identifiers: NCT00096278 (NSABP C-08) and NCT00079274 (NCCTG N0147).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Penney KL, Banbury BL, Bien S, et al. Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. Clin Gastroenterol Hepatol. 2019. PMID: 31811950. doi:10.1016/j.cgh.2019.11.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。